Saturday, October 13, 2007

Cautious Optimism For New Alzheimer's Medications, Reports The Harvard Mental Health Letter

Alzheimer's disease takes a long time to develop, which suggests that it may be
possible to design drugs that work early in the disease process, to delay the
start of symptoms. Over the past decade, researchers have been testing a number
of such "disease-modifying" drugs that target the earliest biological changes in
Alzheimer's, reports the October 2007 issue of the Harvard Mental Health
Letter. None of the disease-modifying drugs now in development will cure
Alzheimer's. But a number of them are currently in phase III clinical trials,
the last stage before the FDA will consider approving the drugs for sale. Media
interest has already begun to intensify. In June, for example, the AARP Bulletin
trumpeted on its cover: "Finally, new drugs offer real hope for reversing the

blog it
For more Insight into Alzheimer's Disease
Subscribe to The Alzheimer's Reading Room

Bob DeMarco is an Alzheimer's caregiver and editor of the Alzheimer's Reading Room. The Alzheimer's Reading Room is the number one website on the Internet for advice and insight into Alzheimer's disease. Bob taught at the University of Georgia, was an executive at Bear Stearns, the CEO of IP Group, and is a mentor. He has written more than 700 articles with more than 18,000 links on the Internet. Bob resides in Delray Beach, FL.

More from the Alzheimer's Reading Room